Abstract：Objective To systematically evaluate the efficacy and safety of bosentan in the treatment of persistent pulmonary hypertension of the newborn (PPHN). Methods Chinese Journal Full-text Database, Weipu Database, Wanfang Data, China Biology Medicine disc, PubMed, Web of Science, Embase, and Cochrane Library were searched for literature on bosentan in the treatment of PPHN published up to August 31, 2021. Results A total of 8 randomized controlled trials were included for Meta analysis. The results of the Meta analysis showed that compared with the control group, the bosentan treatment group had a significantly lower treatment failure rate (RR=0.23, P<0.001), a significantly greater reduction in pulmonary artery pressure [mean difference (MD)=-11.79, P<0.001)], significantly greater increases in oxygen partial pressure (MD=10.21, P=0.006) and blood oxygen saturation (MD=8.30, P<0.001), and a significantly shorter length of hospital stay (MD=-1.35, P<0.001). The descriptive analysis showed that the bosentan treatment group had a lower degree of tricuspid regurgitation than the control group after treatment. The main adverse reactions of bosentan treatment included abnormal liver function, anemia and edema. The results of subgroup analysis based on treatment regimen, research area, and drug dose were consistent with those before stratification. Conclusions Bosentan is effective in the treatment of PPHN. However, when using bosentan, attention should be paid to adverse reactions such as abnormal liver function.
LI Ling-Xue,WEI Bing,YANG Ming et al. Efficacy and safety of bosentan in the treatment of persistent pulmonary hypertension of the newborn: a Metaanalysis[J]. CJCP, 2022, 24(3): 319-325.
Abman SH, Hansmann G, Archer SL, et al. Pediatric pulmonary hypertension: guidelines from the American Heart Association and American Thoracic Society[J]. Circulation, 2015,132(21):2037-2099. PMID: 26534956. DOI:10.1161/CIR.0000000000000329.
6 Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions: version 5.1.0[EB/OL]. (2011-03-20)[2020-10-06].
Mohamed WA, Ismail M. A randomized, double-blind, placebo-controlled, prospective study of bosentan for the treatment of persistent pulmonary hypertension of the newborn[J]. J Perinatol, 2012, 32(8): 608-613. PMID: 22076415. DOI: 10.1038/jp.2011.157.
Steinhorn RH, Fineman J, Kusic-Pajic A, et al. Bosentan as adjunctive therapy for persistent pulmonary hypertension of the newborn: results of the randomized multicenter placebo-controlled exploratory trial[J]. J Pediatr, 2016, 177: 90-96.e3. PMID: 27502103. DOI: 10.1016/j.jpeds.2016.06.078.
Fatima N, Arshad S, Quddusi AI, et al. Comparison of the efficacy of sildenafil alone versus sildenafil plus bosentan in newborns with persistent pulmonary hypertension[J]. J Ayub Med Coll Abbottabad, 2018, 30(3): 333-336. PMID: 30465360.
11 Farhangdoust S, Mehralizadeh S, Bordbar A. Comparison of the effects of bosentan and sildenafil in the treatment of persistent pulmonary arterial hypertension in infants[J]. J Clin Neonatol, 2020, 9(4): 249-254. DOI: 10.4103/jcn.JCN_5_20.
14 Vijay Kumar JR, Natraj Setty HS, Jayaranganath M, et al. Efficacy, safety and tolerability of bosentan as an adjuvant to sildenafil and sildenafil alone in persistent pulmonary hypertension of newborn (PPHN)[J]. Interv Med Appl Sci, 2021, 11(4): 216-220. DOI: 10.1556/1646.2020.00004.
Jain A, McNamara PJ. Persistent pulmonary hypertension of the newborn: advances in diagnosis and treatment[J]. Semin Fetal Neonatal Med, 2015, 20(4): 262-271. PMID: 25843770. DOI: 10.1016/j.siny.2015.03.001.
Zhang W, Wu YE, Yang XY, et al. Oral drugs used to treat persistent pulmonary hypertension of the newborn[J]. Expert Rev Clin Pharmacol, 2020, 13(12): 1295-1308. PMID: 33180564. DOI: 10.1080/17512433.2020.1850257.
Goissen C, Ghyselen L, Tourneux P, et al. Persistent pulmonary hypertension of the newborn with transposition of the great arteries: successful treatment with bosentan[J]. Eur J Pediatr, 2008, 167(4): 437-440. PMID: 17701214. DOI: 10.1007/s00431-007-0531-y.
Nakwan N, Choksuchat D, Saksawad R, et al. Successful treatment of persistent pulmonary hypertension of the newborn with bosentan[J]. Acta Paediatr, 2009, 98(10): 1683-1685. PMID: 19523174. DOI: 10.1111/j.1651-2227.2009.01386.x.
Radicioni M, Bruni A, Camerini P. Combination therapy for life-threatening pulmonary hypertension in a premature infant: first report on bosentan use[J]. Eur J Pediatr, 2011, 170(8): 1075-1078. PMID: 21380943. DOI: 10.1007/s00431-011-1422-9.
Maneenil G, Thatrimontrichai A, Janjindamai W, et al. Effect of bosentan therapy in persistent pulmonary hypertension of the newborn[J]. Pediatr Neonatol, 2018, 59(1): 58-64. PMID: 28735030. DOI: 10.1016/j.pedneo.2017.02.003.
Humbert M, Segal ES, Kiely DG, et al. Results of European post-marketing surveillance of bosentan in pulmonary hypertension[J]. Eur Respir J, 2007, 30(2): 338-344. PMID: 17504794. DOI: 10.1183/09031936.00138706.
Wolf D, Tseng N, Seedorf G, et al. Endothelin-1 decreases endothelial PPARγ signaling and impairs angiogenesis after chronic intrauterine pulmonary hypertension[J]. Am J Physiol Lung Cell Mol Physiol, 2014, 306(4): L361-L371. PMID: 24337925. PMCID: PMC3920227. DOI: 10.1152/ajplung.00277.2013.
